Abstract |
IgE-mediated mast cell and basophil activation initiates immediate and late-phase allergic responses, and plays a pivotal role in the pathogenesis of allergic diseases such as bronchial asthma and allergic rhinitis. Thus, the blocking of the binding of IgE to the high affinity receptors for IgE ( Fc epsilon RI) on mast cells and basophils may prevent dual responses, and improve allergic symptoms. A recombinant humanized monoclonal antibody (rhuMAb-E25) forms complexes with free IgE, blocks its binding to mast cells and basophils, and inhibits allergen-induced mediator release from both cells and attenuates immediate and late-phase reactions to inhaled allergens. In clinical trials, the therapy with rhuMAb-E25 was effective in patients with atopic asthma and allergic rhinitis and well tolerated. This antibody seems to be promising as a treatment for atopic asthma and allergic rhinitis.
|
Authors | Y Morita |
Journal | Nihon rinsho. Japanese journal of clinical medicine
(Nihon Rinsho)
Vol. 59
Issue 10
Pg. 2019-22
(Oct 2001)
ISSN: 0047-1852 [Print] Japan |
PMID | 11676148
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- rhuMAb-E25
- Immunoglobulin E
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Basophils
(immunology)
- Clinical Trials as Topic
- Humans
- Hypersensitivity, Immediate
(immunology, therapy)
- Immunoglobulin E
(immunology)
- Mast Cells
(immunology)
|